08:53 AM EDT, 03/17/2025 (MT Newswires) -- Pliant Therapeutics ( PLRX ) said Monday that interim data from its phase 1 dose escalation trial evaluating PLN-101095, in combination with pembrolizumab, showed antitumor activity in patients with immune checkpoint inhibitor-refractory advanced or metastatic solid tumors.

The company said PLN-101095 was generally well tolerated across the doses tested in three of five potential cohorts of the study. Half of the six patients receiving the highest dose tested of 1000 mg twice daily showed partial responses, according to Pliant.

The trial is currently enrolling the fourth cohort, which will evaluate PLN-101095 at 1000 mg three times daily, the company said.